HOOKIPA Pharma (HOOK) announced the promotion of Katia Schlienger, M.D., Ph.D., to Chief Medical Officer, CMO, and the appointment of Malte Peters, M.D., to its Board of Directors, both effective January 1, 2023. Dr. Schlienger has been promoted to Chief Medical Officer. She has served as the Company’s Executive Vice President, Clinical Research and Development since July 2022. Dr. Peters serves as Chief Research and Development Officer at MorphoSys (MOR) and will retire from the company at the end of 2022.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HOOK:
- HOOKIPA Pharma Appoints Katia Schlienger, M.D., Ph.D., Chief Medical Officer and Malte Peters, M.D., to Board of Directors
- Hookipa Pharma downgraded to Underperform from Buy at BofA
- Hookipa Pharma reports Q3 EPS (25c), consensus (28c)
- HOOKIPA Pharma Announces Third Quarter 2022 Financial Results and Provides a Business Update
- HOOKIPA Pharma to Report Third Quarter 2022 Financial Results and Corporate Updates on November 14, 2022